Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction;...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Target Price
The average target price of DSGN is 14 and suggests 34% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell